Reasons for the discrepancies between these 2 studies of heart failure subjects are unknown but could involve differences in treatment duration, the fact that the former study was open-label and non-randomized, as well as the type of GLP-1R agonist utilized. The gene discussed is GLP1R; the disease is heart failure.